Efavirenz in an obese HIV-infected patient - a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
| Data(s) |
2012
|
|---|---|
| Resumo |
Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing. |
| Identificador |
http://serval.unil.ch/?id=serval:BIB_2B532405FD6A isbn:2040-2058 (Electronic) pmid:22910127 doi:10.3851/IMP2107 isiid:000311240000020 |
| Idioma(s) |
en |
| Fonte |
Antiviral Therapy, vol. 17, no. 7, pp. 1381-1384 |
| Tipo |
info:eu-repo/semantics/article article |
